We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
i2O Therapeutics, a biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc.